Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$6.00 USD
-0.17 (-2.76%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $5.98 -0.02 (-0.33%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVCT 6.00 -0.17(-2.76%)
Will NVCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCT
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
NVCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Other News for NVCT
Nuvectis Pharma Inc Reports Q2 2025 EPS of -$0. ...
Nuvectis Pharma GAAP EPS of -$0.30
Nuvectis Pharma (NVCT) Strengthens Position with Promising Trial Results
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | ...
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year